Should Biotechnology Stock Impel Pharmaceuticals Inc (IMPL) Be in Your Portfolio Monday?

Monday, November 27, 2023 09:36 AM | InvestorsObserver Analysts

Mentioned in this article

Should Biotechnology Stock Impel Pharmaceuticals Inc (IMPL) Be in Your Portfolio Monday?

Impel Pharmaceuticals Inc (IMPL) is around the top of the Biotechnology industry according to InvestorsObserver. IMPL received an overall rating of 80, which means that it scores higher than 80 percent of all stocks. Impel Pharmaceuticals Inc also achieved a score of 95 in the Biotechnology industry, putting it above 95 percent of Biotechnology stocks. Biotechnology is ranked 53 out of the 148 industries.

IMPL has an Overall Score of 80. Find out what this means to you and get the rest of the rankings on IMPL!

See Full IMPL Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 80 would rank higher than 80 percent of all stocks. This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Impel Pharmaceuticals Inc Stock Today?

Impel Pharmaceuticals Inc (IMPL) stock is trading at $0.73 as of 9:36 AM on Monday, Nov 27, a loss of -$0.11, or -13.56% from the previous closing price of $0.84. The stock has traded between $0.63 and $0.74 so far today. Volume today is below average. So far 289,348 shares have traded compared to average volume of 1,746,902 shares. Click Here to get the full Stock Report for Impel Pharmaceuticals Inc stock.